Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

NCT03761914 is registered in ClinicalTrials.gov with Sellas Life Sciences Group as lead sponsor.

NCT NCT03761914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03761914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Lead sponsor
Sellas Life Sciences Group
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2019
Completion date
October 27, 2022
Enrollment
26 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, colorectal cancer, ovarian cancer, small-cell lung cancer, triple-negative breast cancer